Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$58.5 million.

  • Centessa Pharmaceuticals' Free Cash Flow fell 17328.57% to -$58.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$181.0 million, marking a year-over-year decrease of 3887.26%. This contributed to the annual value of -$142.1 million for FY2024, which is 1147.71% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Free Cash Flow of -$58.5 million as of Q3 2025, which was down 17328.57% from -$22.5 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Free Cash Flow high stood at -$21.4 million for Q3 2024, and its period low was -$60.1 million during Q2 2022.
  • Its 4-year average for Free Cash Flow is -$42.8 million, with a median of -$42.8 million in 2024.
  • Examining YoY changes over the last 5 years, Centessa Pharmaceuticals' Free Cash Flow showed a top increase of 4467.23% in 2025 and a maximum decrease of 17328.57% in 2025.
  • Centessa Pharmaceuticals' Free Cash Flow (Quarter) stood at -$52.2 million in 2022, then skyrocketed by 40.48% to -$31.1 million in 2023, then crashed by 37.72% to -$42.8 million in 2024, then tumbled by 36.79% to -$58.5 million in 2025.
  • Its Free Cash Flow stands at -$58.5 million for Q3 2025, versus -$22.5 million for Q2 2025 and -$57.2 million for Q1 2025.